CSPC PHARMACEUTICAL (CVG BE) stock market data APIs
€0.9594
0(0%)
as of October 17, 2025
Try our APIs with
free plan!
CSPC PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for CVG.BE.
Prev. Close
0.9594
Open
0.9594
High
0.9594
Low
0.9594
52 wk Range
0.5016-1.2081
Market Cap
11 678 M
Dividends (Yield)
0.0963
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSPC PHARMACEUTICAL data using free add-ons & libraries
Get CSPC PHARMACEUTICAL Fundamental Data
CSPC PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSPC PHARMACEUTICAL News
New
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), ...
How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook
The Board of Directors of CSPC Pharmaceutical Group recently announced that its novel SYH2070 siRNA injection received regulatory approval to begin clinical trials in both the U.S. and China for the t...
Analysis-Innovent's weight-loss drug highlights China challenge for Novo, Lilly
By Andrew Silver SHANGHAI (Reuters) -Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a ...
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Co...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
